RxDoctor Payments Data

Carmen Serrano, MD

Neurology · San Juan, PRNPI 1992781595

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $2,800 of the $4,186 with a category attached, or 66.9%. AbbVie accounts for 75.7% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2022 at $3,114 and has fallen 93.0% since, to $218 in 2025.

$4,186in general payments, 2019–2025

Across 42 payments — averaging $99.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • AstraZeneca$190
  • Novartis$172
  • EMD Serono, Inc.$172
  • Amneal Pharmaceuticals LLC$146
  • Biogen$92
  • plus $246 from 10 others
$180,418in research payments, 2019–2025

Across 20 payments — averaging $9020.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly Export S.A. Puerto Rico Branch$159K
  • AbbVie$19K
  • Eli Lilly$3K

What the payments were for

  • Consulting fees$2,80067%
  • Speaking & faculty fees$211%
  • Food & beverage$1,36533%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,186 in reported general payments places this provider in the 70th percentile of 129 neurology providers in Puerto Rico.

See all neurology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$15,430
Medicare patients
32
Services billed
1,143

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate13$107,536
NuplazidPimavanserin Tartrate15$75,181
RytaryCarbidopa/Levodopa65$51,915
NeuproRotigotine13$10,993
Carbidopa-LevodopaCarbidopa/Levodopa138$4,547
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone33$4,389
Entacapone13$1,820
Rasagiline Mesylate15$1,802
Carbidopa-Levodopa ErCarbidopa/Levodopa45$1,006
Primidone22$730
Memantine Hcl56$712
Clonazepam41$679
RivastigmineRivastigmine Tartrate15$598
Pramipexole DihydrochloridePramipexole Di-Hcl32$523
Donepezil Hcl53$355

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$23$75,18115 claims
Amneal Pharmaceuticals LLCRytary$146$51,91565 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 129 neurology providers in Puerto Rico.

Other neurology in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →